Who are AIT Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ragweed pollen, GRASS 2800 BAU, PURETHAL Grasses, 20.000 AUM/ml, Staloral TM, House dust mite Novo Helisen Depot, sublingual immunotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ait-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AIT Tablet — Competitive Intelligence Brief

AIT Tablet (AIT Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

marketed Allergen immunotherapy Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

AIT Tablet (AIT Tablet) — ALK-Abelló A/S. AIT Tablet is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through gradual oral exposure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AIT Tablet TARGET	AIT Tablet	ALK-Abelló A/S	marketed	Allergen immunotherapy
ragweed pollen	ragweed pollen	The University of Texas Medical Branch, Galveston	marketed	Allergen immunotherapy
GRASS 2800 BAU	GRASS 2800 BAU	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy extract	Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species)
PURETHAL Grasses, 20.000 AUM/ml	PURETHAL Grasses, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Grass pollen allergens (IgE and T-cell epitopes)
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
House dust mite Novo Helisen Depot	House dust mite Novo Helisen Depot	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
sublingual immunotherapy	sublingual immunotherapy	University of Genova	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AIT Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ait-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab